Compare Allstate Corp (ALL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs BioNano Genomics Inc — how do they compare? Allstate Corp trades at $256.7 (market cap $66.31B), while BioNano Genomics Inc trades at $1.24 (market cap $13.66M). The key difference: Allstate Corp is far larger — about 4854.3× BioNano Genomics Inc's market cap, and Allstate Corp pays a 1.65% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ALL | BNGO | |
|---|---|---|
Market Cap | $66.31B | $13.66M |
Sector | Financials | Health |
52-Week High | $275.11 | $4.92 |
52-Week Low | $190.00 | $1.06 |
Enterprise Value | $74.96B | $16.26M |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $256.24, down 4.98% on the day, but remains near recent highs with strong technical support at $253. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, driven by improved underwriting and investment income. Revenue growth has accelerated from $51.4B in 2022 to $67.1B in 2025, with net income margin expanding to 19.19%. Analyst consensus is a Buy with a $266.47 price target, though sentiment is mixed on sustainability of peak profitability.
Outlook is positive given earnings momentum and attractive valuation (P/E 5.25), but risks include potential normalization of underwriting margins and macroeconomic sensitivity. The stock offers value with high ROE (49.11%) and consistent dividend payments, yet investors should weigh cyclical insurance pressures against fundamental strength.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
